Format

Send to

Choose Destination
Clin Sci (Lond). 2009 Nov 23;118(5):315-32. doi: 10.1042/CS20090399.

Insulin resistance and hyperinsulinaemia in the development and progression of cancer.

Author information

1
Endocrinology and Metabolic Medicine, Imperial College London, Praed Street, London W2 1PG, U.K. i.godsland@imperial.ac.uk

Abstract

Experimental, epidemiological and clinical evidence implicates insulin resistance and its accompanying hyperinsulinaemia in the development of cancer, but the relative importance of these disturbances in cancer remains unclear. There are, however, theoretical mechanisms by which hyperinsulinaemia could amplify such growth-promoting effects as insulin may have, as well as the growth-promoting effects of other, more potent, growth factors. Hyperinsulinaemia may also induce other changes, particularly in the IGF (insulin-like growth factor) system, that could promote cell proliferation and survival. Several factors can independently modify both cancer risk and insulin resistance, including subclinical inflammation and obesity. The possibility that some of the effects of hyperinsulinaemia might then augment pro-carcinogenic changes associated with disturbances in these factors emphasizes how, rather than being a single causative factor, insulin resistance may be most usefully viewed as one strand in a network of interacting disturbances that promote the development and progression of cancer.

PMID:
19922415
PMCID:
PMC2782313
DOI:
10.1042/CS20090399
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center